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Serotonin (5-HT) plays a major yet complex role in modulating spinal nociceptive
transmission as a consequence of the number of 5-HT receptor subtypes. These include
the 5-HT2 receptor, which is further sub classified into 5-HT2A, B and C. Studies have
described both a pro- and antinociceptive action following 5-HT2A-receptor activation;
therefore, to shed light on the directional nature of spinal 5-HT2A receptor activity, we
investigated the effects of spinal administration of the 5-HT2A receptor antagonist,
ketanserin, on the evoked responses of dorsal horn neurones to electrical, mechanical
and thermal stimulation. We also assessed the effects of systemic administration of
ritanserin, a 5-HT2A/2C receptor antagonist and spinal application of (±)-2,5-Dimethoxy-4-
iodoamphetamine hydrochloride (DOI) (3.6 and 17.8 μg/50 μl), a 5-HT2A/2C agonist, on the
same evoked neuronal responses. Ketanserin (1, 10 and 100 μg/50 μl) produced a dose related
inhibition of the evoked responses to noxious mechanical punctate and thermal stimuli
only. Ritanserin (2 mg/kg) replicated the inhibitory effects seen with ketanserin on the
natural evoked neuronal responses and also potently inhibited the C-fibre, post discharge,
input and wind-up evoked responses. DOI increased the mechanical and thermal evoked
responses, an effect reversed by ketanserin. Thus, our findings show that spinal ketanserin
(1–100 μg/50 μl) and systemic ritanserin (2 mg/kg), at these doses, have similar
antinociceptive effects, whereas the agonist, DOI, produced excitatory effects, on spinal
neuronal activity. Our data, therefore, supports a pronociceptive role for 5-HT2 receptors,
most likely through modulation of 5-HT2A receptor activity, on spinal nociceptive
transmission under normal conditions.
© 2011 Elsevier B.V. 
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1. Introduction
Descending modulation from brainstem areas of spinal
nociceptive transmission is a well-documented phenomenon.
Most early studies describe a role for descending inhibitory
control of spinal nociceptive activity mediated primarily by
noradrenergic and serotonergic (5-HT) pathways, but more
recently, the role of descending facilitation from the brain-
stem, onto spinal nociceptive pathways, has stimulated
intense research and, in particular, the role for 5-HT in
mediating this excitatory drive (Bannister et al., 2009; Wei
et al., 2010).
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30 B R A I N R E S E A R C H 1 3 8 2 ( 2 0 1 1 ) 2 9 – 3 6Serotonergic input to the dorsal horn of the spinal cord
derives almost entirely from supraspinal sources, with a
minor contribution from local spinal neurones. 5-HT path-
ways, running directly from the rostral ventromedial medulla
(RVM; the site of origin of the serotonergic descending
pathway) to the spinal cord, comprise one of the main
neurotransmitter systems mediating descending modulation
of spinal neuronal activity. Animal studies report variably on
the function of descending controls from the RVM and of 5-HT
in nociceptive transmission (Bannister et al., 2009; Millan,
2002). Early studies investigating blockade of RVM activity and
loss of 5-HT modulation have pointed to a loss of inhibitory
control resulting in increased pain behaviours (Millan, 2002).
However, in addition to descending inhibition, a wealth of
evidence now exists for a descending excitatory drive from the
RVM modulating spinal nociceptive transmission, which
involves the activation of serotonergic pathways (Bannister
et al., 2009; Dogrul et al., 2009; Wei et al., 2010).
The heterogeneous nature of the 5-HT receptor family
underlies the bidirectional effect of the neurotransmitter. To
date, seven different receptor subfamilies have been identified
which vary with respect to their localisation, coupling and
ligand binding properties (Alexander et al., 2008). A number of
reports have linked descending facilitation from the brain-
stem to activation of spinal 5-HT3 receptors (Dogrul et al.,
2009; Rygh et al., 2006; Suzuki et al., 2002; Svensson et al.,
2006). For instance, using in vivo electrophysiologicalmethods,
we have demonstrated a pro-nociceptive function for spinal
5-HT3 receptors on spinal neuronal activity since topical
spinal application of the selective antagonist ondansetron
significantly reduced spinal neuronal activity in normal and
pathaphysiological conditions (Rahman et al., 2004; Suzuki
et al., 2002; Suzuki et al., 2004). This pronociceptive role for
spinal 5-HT3 receptors has also been borne out by behavioural
and anatomical studies (Dogrul et al., 2009; Oatway et al., 2004;
Svensson et al., 2006; Zeitz et al., 2002) but disputed by others
(Peters et al., 2010), although a pronociceptive role of
endogenous spinal 5-HT was demonstrated by the reduction
in nociceptive responses following selective depletion of
spinal 5-HT (Dogrul et al., 2009; Oatway et al., 2004; Rahman
et al., 2006). Nonetheless, descending serotonergic facilitation
may not be exclusive to 5-HT activating the 5-HT3 receptor, as
there are several lines of evidence pointing to a pronocicep-
tive role for the 5-HT2 receptor, although controversy exists.
The complexity of effects produced by 5-HT acting on 5-HT2
receptors is due to the further existence of subtypes, namely
5-HT2A, 2B and 2C receptors (Alexander et al., 2008). Of these,
the evidence to date largely points to a pronociceptive role for
the 5-HT2A subtype (Eide and Hole, 1991; Kjorsvik et al., 2001;
Nishiyama, 2005; Silveira et al., 2010; Thibault et al., 2008) but
see (Honda et al., 2006; Kommalage and Hoglund, 2005; Sasaki
et al., 2001; Sasaki et al., 2003), and an antinociceptive role for
the 5-HT2C receptor subtypes inmodulating spinalnociceptive
transmission (Aira et al., 2010; Liu et al., 2007; Obata et al., 2004;
Obata et al., 2007). The amino acid sequence of the 5-HT2
receptors share a high degree of homology within the seven
transmembrane domains; thus, it is not surprising that
conflicting reports exist within the literature since many
compounds bind to each subtype with high affinity (Knight
etal., 2004). Behavioural studies could be confounded by themultiple functions of 5-HT in the CNS. Here, we evaluate the
effect of topical spinal application of the selective 5-HT2A
receptor antagonist, ketanserin, on the evoked responses of
wide dynamic range dorsal horn neurones in response to
electrical and natural stimulation of the peripheral receptive
field, in order to evaluate the spinal specific role of this receptor
subtype in suprathreshold responses. Ketanserin potently
blocks 5-HT2A receptors, less potently blocks 5-HT2C recep-
tors, and has no significant effect on 5-HT3 or 5-HT4 receptors
or any members of the 5-HT1 receptor family (Knight et al.,
2004). We also assessed the effects of systemic delivery of the
5-HT2A/2C antagonist, ritanserin, on the same neuronal
measures. Ritanserin has equal affinity for the 5-HT2A and
2C subtypes (Knight et al., 2004), and finally, we assessed the
effects of spinal application of (±)-2,5-Dimethoxy-4-iodoam-
phetamine hydrochloride (DOI), a mixed 5-HT2A/2C agonist,
but with greater relative selectivity for 5-HT2A receptors, on
these evoked spinal neuronal responses.2. Results
2.1. Effect of topical spinal administration of ketanserin on
evoked dorsal horn neuronal responses
Spinally applied ketanserin (1, 10 and 100 μg/50 μl) did not
produce any significant effects on any of the electrically
evoked neuronal measures, although a trend towards a dose-
related inhibition was observed for the Aδ-, C-fibre and input
evoked responses (Fig. 1a).
In contrast a significant dose-related inhibition was
observed on the natural evoked neuronal responses. This
was evidenced as the lower dose was ineffective and the two
highest doses produced a significant inhibition of the noxious
heat and mechanical punctate evoked neuronal responses
(Fig. 1b and c).
Spinal application of cumulative doses of ketanserin
inhibited neuronal responses to mechanical stimuli, seen as
significant decreases in evoked neuronal response to stimu-
lation with von Frey 26 and 60 g (significant at 10 μg and
100 μg, p<0.05 2-way RM ANOVA). Significant inhibition of the
evoked neuronal responses was also observed in response
heat stimulation at 45 °C (significant 100 μg, p<0.05 2-way RM
ANOVA) and 48 °C (significant at 10 μg and 100 μg, p<0.05
2-way RM ANOVA) (Fig. 1c).
Spinal application of ketanserin did not significantly
inhibit any of the low-intensity innocuous mechanical (vF 2
and 8 g) and heat (35–40 °C) evoked responses nor the evoked
response to noxious heat at 50 °C (Fig. 1b and c).
2.2. Effect of systemic administration of ritanserin on
evoked dorsal horn neuronal responses
Ritanserin (2 mg/kg) significantly inhibited only the nocicep-
tive specific elements of the electrical evoked neuronal
response. This was seen as marked reductions in the evoked
response to the C-fibre, post discharge, input and wind-up
(p<0.05, paired t-test) (Fig. 2a).
An overall inhibition of the natural mechanical and
thermal evoked responses were observed following systemic
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control responses. Significance was seen in response to
stimulation with vF 60 g and 48 °C heat (p<0.05 2-way RM
ANOVA). Although ritanserin clearly reduced the responses to
the lower von Frey and heat stimuli tested, these did not quite
reach significance (Fig. 2b and c). Interestingly, systemic
administration of ritanserin produced near identical inhibi-
tions to those seen with ketanserin with respect to the
mechanical and thermal evoked neuronal responses, al-
though the former drug produced greater inhibitions of the
noxious electrical evoked responses (C-fibre, post discharge,Fig. 1 – Effect of topical spinal administration of ketanserin
(1, 10 and 100 μg/50 μl) on the a. electrical b. mechanical
punctate and c. thermal evoked responses of wide dynamic
range dorsal horn neurones. Ketanserin significantly
inhibited the noxious mechanical (26 and 60 g) and heat
(45–48 °C) evoked neuronal responses, evoked responses of
wide dynamic range dorsal horn neurones. Data expressed
as mean±SEM. Significance at the lower dose of 10 μg/μl is
denoted by +, whereas significance at the higher dose of
100 μg/μl is denoted by *p<0.05.
Fig. 2 – Effect of systemic administration of ritanserin
(2 mg/kg) on a. electrical b. mechanical punctate and
c. thermal evoked responses of wide dynamic range dorsal
horn neurones. Ritanserin significantly inhibited the
electrically evoked C-fibre, post discharge, input and
wind-up neuronal responses. The evoked response to
noxious mechanical (60 g) and heat (48 °C) stimuli was also
significantly inhibited. Data expressed as mean±SEM.
Significance is denoted by *p<0.05.input and wind-up) (Fig. 2a), as compared with the effects
observed with ketanserin on the same electrical measures
(Fig. 1a).
2.3. Effect of topical spinal administration of
(±)-2,5-Dimethoxy-4-iodoamphetamine hydrochloride
(DOI) on evoked dorsal horn neuronal responses
Spinal application of DOI did not produce any significant
overall change in the electrical evoked neuronal responses
(Fig. 3a). A trend towards a facilitation of the electrical C-fibre,
post-discharge and input evoked neuronal responses was
Fig. 3 – Effect of topical spinal administration of DOI (3.6 and
17.8 μg/50 μl) on a. electrical b. mechanical punctate and
c. thermal evoked responses of wide dynamic range dorsal
horn neurones. DOI significantly increased the evoked
response to mechanical (26 and 60 g) and heat (48 °C) stimuli.
Data expressed as mean±SEM. Significance is denoted by
*p<0.05.
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comparison the wind-up response tended to be inhibited by
DOI. This effect may be partly due to the DOI induced increase
in the input response. Wind-up is calculated as the number of
“extra” neuronal responses evoked from a train of 16 electrical
pulses after subtraction of the input response. Given that the
input response tended to be facilitated by DOI, this resulted in
a lowered wind-up value. This also suggests that DOI is more
likely to have presynaptic site of action since the input gives a
measure of the baseline C-fibre afferent input to the spinal
cord prior to any spinal or supraspinalmodulation of neuronal
responses.
Spinal application of DOI resulted in an overall increase in
the evoked neuronal responses to mechanical punctate
stimuli, seen as a significant increase in evoked neuronal
response to stimulation with von Frey 26 and 60 g (significant
at 17.8 μg, p<0.05 2-way RMANOVA) (Fig. 3b). The DOI induced
increase in mechanical evoked neuronal response wasreversed back towards baseline levels by spinal application
of ketanserin (1 μg).
The effect of DOI on the thermal evoked responses was
more variable. Spinal application of DOI on the evoked
response to 40 °C and 45 °C heat in 2 of the 6 cells resulted in
a clear and sustained inhibition with one or both doses of DOI.
Furthermore, in some instances, a transitory reduction was
seen at the early (10 min.) time point to the evoked response to
40 °C and 45 °C stimuli; these inhibitory effects of DOI on these
thermal stimuli were dwarfed by a marked facilitation of the
neuronal response at the later time points (30 and 50 min.)
post DOI administration. By contrast the evoked neuronal
response to 48 °C was clearly facilitated (significant at 17.8 μg,
p<0.05 2-way ANOVA). The increased heat evoked neuronal
responses produced by DOI were reversed back towards
baseline levels by spinal application of ketanserin (Fig. 3c).3. Discussion
There is considerable evidence for the critical role for
serotonin (5-HT) in the modulation of spinal nociceptive
transmission. A number of early studies observed inhibition
and subsequent analgesia following blockade of the 5-HT
system; more recently, however, a pronociceptive/hyperalge-
sic action has also emerged for the 5-HT system (for review see
Bannister et al. (2009)). These contrary reports can, in part, be
accounted for by the multiplicity of neuronal targets and
receptor subtypes upon which 5-HT acts (Knight et al., 2004).
To date, seven distinct families of 5-HT receptors have been
identified (5-HT1–5-HT7), and several of these have been
further sub-classified. Among them, the 5-HT2 receptor is
thought to play an important role in spinal pain modulation;
however, as is the case for other 5-HT receptor subtypes,
opposing data exist as to the direction of effect (pro- or
antinociceptive) produced by 5-HT2 receptor modulation. Our
electrophysiological data show that the 5-HT2A antagonist,
ketanserin (10–100 μg/50 μl), and the 5-HT2A/2C antagonist,
ritanserin (2 mg/kg), at these doses, have an overall inhibitory
effect on spinal neuronal activity with selectivity for the
higher intensity responses; furthermore, the 5-HT2A/2C
receptor agonist, DOI, produced an overall facilitation of
spinal neuronal responses with significant effects seen on
the mechanical and thermal evoked neuronal responses.
These increased neuronal responses were reversed by spinal
application of ketanserin. Thus, our data support a pronoci-
ceptive role for the 5-HT2 receptor, most likely through
targeting the 5-HT2A receptor subtype, on spinal nociceptive
transmission under normal conditions.
There are several lines of evidence for a pronociceptive role
for the 5-HT2 receptor, which is likely due to activity at the
5-HT2A receptor subtype. The 5-HT2A receptor has been shown
tobewidelydistributed throughout thespinal cordand ispresent
at presynaptic and postsynaptic sites therein. This receptor
subtype shows dense labelling in lamina II inner and is therefore
ideally located for modulation of spinal nociceptive processing.
With regards to primary afferent neurones, 5-HT2A receptors are
mainly localised in small andmedium sized DRG neurones with
most 5-HT2A receptor immunolabeled cells expressing the
TRPV1 receptor, thus indicating their nociceptive nature (Doly
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coupled receptor positively coupled to phospholipase C, leading
to an increase in phosphotidylinositol and intracellular calcium.
In vitro electrophysiological recordings have shown a long
lasting synaptic facilitation of superficial dorsal horn neurones
mediated by 5-HT acting at 5-HT2 receptors (Hori et al., 1996).
Taken together, these datawould implicate an excitatory role for
the 5-HT2A receptor in spinal nociceptive transmission.
The findings from behavioural studies are mixed. For
instance, spinal administration of the mixed 5-HT2A/C
agonist, (±)-2,5-dimethoxy-4-iodoamphetamine, (DOI), in-
creased the behavioural response to formalin injection, an
effect reversed by ketanserin (Kjorsvik et al., 2001), and DOI
induced pain-like behaviours such as licking and biting, in line
with a pronociceptive role for 5-HT2 receptors (Eide and Hole,
1991). Similarly, blocking spinal 5-HT2A receptors inhibited
the formalin response (Nishiyama, 2005) and reduced spinal
FOS activation in a paw incisionmodel (Silveira et al., 2010). In
direct contrast to the aforementioned studies, intrathecal
administration of 5-HT2A/2C receptor agonists reversed the
behavioural pain-like responses to formalin and chronic
constriction nerve injury. These effects were reversed by
pretreatment with intrathecal administration of ketanserin,
therefore implicating spinal 5-HT2A receptors in mediating
the antinociceptive effects of 5-HT (Sasaki et al., 2001; Sasaki
et al., 2003), and 5-HT2A receptor induced spinal acetylcholine
release and consequent antinociception was demonstrated
(Kommalage and Hoglund, 2005) In rat models of chemother-
apy and HIV-therapy induced neuropathy, however, a signif-
icant increase in 5-HT2AR immunoreactivity was seen in the
superficial layers of the lumbar dorsal horn and an epidural
injection of a selective 5-HT2A receptor antagonist dose-
dependently decreased the thermal and mechanical hyper-
sensitive behaviours; furthermore 5-HT2A receptor knockout
mice did not develop HIV-therapy or chemotherapy-induced
neuropathic pain behaviours whereas control littermates
displayed a neuropathy comparable to that observed in rats
(Thibault et al., 2008). By contrast, in a partial sciatic nerve
ligation mouse model of neuropathic pain the inhibitory
antiallodynic effects of a selective serotonin reuptake inhib-
itor was reversed by ketanserin (Honda et al., 2006). These
discrepancies within the literature may be due to differences
in the pain test or animal species used and also due to the
inability of ligands used in earlier studies to sufficiently
discriminate between 5-HT2A and 5-HT2C receptors.
The 5-HT2C receptor is present in the dorsal horn of the
spinal cord, with 5-HT2C receptor mRNA expressed at high
levels in most of the grey matter, except for lamina II (Fonseca
et al., 2001). This receptor subtype is likely to have a
predominant postsynaptic localization, since 5-HT2C mRNA
was undetected in naïve rat DRG (Nicholson et al., 2003; Wu
et al., 2001) but are expressed de novo in rat DRG after
inflammation (Wu et al., 2001). The 5-HT2C receptor shares
similar pharmacological and transductional features with the
5-HT2A receptor; however, with regards to modulation of
spinal nociceptive transmission, a number of recent studies
have assigned an antinociceptive role for this receptor
subtype. For example, intrathecal administration of selective
5-HT2C receptor agonists attenuated pain-related behaviour
in a rat model of trigeminal and spinal nerve ligated model ofneuropathic pain, which may involve activation of spinal
noradrenergic mechanisms (Nakai et al., 2010; Obata et al.,
2004; Obata et al., 2007). Activation of spinal 5-HT2C receptors
was also shown to reduce the C-fibre evoked spinal field
potentials in spinal nerve ligated and sham control rats (Aira
et al., 2010), and the selective 5-HT2C receptor antagonist RS
102221 reversed the inhibitory effect of spinal 5-HT on the
evoked response of dorsal horn wide dynamic range neurons
(Liu et al., 2007).
The 5-HT2 receptors have a very high amino-acid sequence
homology and thus many compounds have an affinity for all
three subtypes. Despite the selectivity limitations of drugs
targeting 5-HT2 receptors, the emerging consensus, from the
studies discussed above, points to a pronociceptive role for the
5-HT2A (Eide and Hole, 1991; Kjorsvik et al., 2001; Nishiyama,
2005; Silveira et al., 2010; Thibault et al., 2008) but see (Honda
et al., 2006; Sasaki et al., 2001; Sasaki et al., 2003) and an
antinociceptive role for the 5-HT2C receptor subtypes in
modulating spinal nociceptive transmission (Aira et al., 2010;
Liu et al., 2007; Obata et al., 2004; Obata et al., 2007).
Our findings in the present study demonstrate a clear
pronociceptive role for spinal 5-HT2 receptors, most likely
through targeting the 5-HT2A receptor subtype since the
selective 5-HT2A antagonist ketanserin inhibited evoked
neuronal responses, and in particular, inhibited the noxious
evoked natural mechanical and thermal stimuli. Although
ketanserin is the prototypical antagonist for 5-HT2A receptors,
it also has affinity, but at higher concentrations, for the
5-HT2C receptor. Therefore, we cannot exclude the possibility
that some of ketanserin's effect could be due to the blockade of
5-HT acting at 5-HT2C receptors.
Ritanserin has almost equal affinity for the 5-HT2A and the
(reportedly antinociceptive) 5-HT2C receptor. Nonetheless,
the overall effect of the drug was to reduce neuronal activity.
Ritanserin produced significant inhibition of the electrically
evoked, C-fibre, post discharge, input and wind-up, neuronal
responses, in contrast to ketanserin, where no significant
effect was seen on these electrically evoked neuronal mea-
sures. Both inhibited naturally evoked activity. Since we used
naïve animals with no peripheral inflammation, it is unlikely
that a peripheral action of ritanserin could be responsible. The
difference could be due to a more potent and/or central effect
of ritanserin or actions at supraspinal sites. For instance,
5-HT2A and 2C receptors are expressed within brainstem
nuclei involved in descending pain modulation, e.g., RVM
(Fonseca et al., 2001). However, the receptor here appears to
produce an overall decrease in inhibitory outflow from
descending pathways (de Oliveira et al., 2006; Kiefel et al.,
1992; Queree et al., 2009), and these studies would predict that
ritanserin effect within brainstem nuclei would increase
spinal neuronal activity. However, there is some evidence for
an excitatory response of medullary neurones to 5-HT, which
is blocked by ketanserin (Davie et al., 1988); thus, it is
conceivable that the dose of ritanserin used in our study
could inhibit those neurones within the RVM classified as “ON
cells” andwhich are deemed pain facilitating (Heinricher et al.,
2009) so explaining the differences observed between local
and systemic administration of the 5-HT2 antagonists.
Remarkably, ritanserin produced near identical inhibitory
effects of the mechanical and thermal evoked responses as
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that the route of administration is not a critical factor in the
overall effect of these two antagonists on naturally evoked
neuronal activity and that the spinal cord is an important site
of action of 5-HT2 receptor mediated pain facilitation.
DOI is a mixed 5-HT2A/2C receptor agonist, yet spinal
application of the drug produced an overall increase in the
evoked responses of spinal neurones to mechanical punctate
and thermal stimulation of the peripheral receptive field, an
effect that was reversed by ketanserin. Sasaki et al. (2001 and
2003) demonstrated an antinociceptive effect of DOI on
behavioural responses in models of acute and sustained
pain states; however, these studies used much higher doses
of DOI.We have used lower doses of DOI, which are of a similar
concentration with the doses used in studies demonstrating a
pain-like behavioural syndrome induced by DOI (Eide and
Hole, 1991; Kjorsvik et al., 2001). Thus, our data with the
5-HT2A/2C agonist, DOI, also support the conclusion that
5-HT2 receptors play a pronociceptive role in the spinal
nociceptive transmission, possibly due to a predominant
action of DOI at 5-HT2A receptors.
The overall effect on spinal neuronal activity is dependent
on the interplay between excitatory and inhibitory mecha-
nisms; thus, our data suggest that the overriding effects of
ketanserin and ritanserin were likely to be mediated through
antagonism of the actions of 5-HT acting at 5-HT2A receptors
leading to the reduction in neuronal responses observed in
this study. The consequence of 5-HT2C receptor blockade, at
these doses, on the evoked spinal neuronal responses is
minimal by comparison, if 5-HT2C receptors do indeed have
an antinociceptive role. Similarly, activation of 5-HT2A/2C
receptors with DOI increased neuronal responses, an effect
reversed by ketanserin, thus implicating a predominant
5-HT2A action. An alternative possibility, however, is that
5-HT2C receptors could also have pronociceptive effect on
spinal nociceptive transmission.
The primary source of descending serotonergicmodulation
of ascending nociceptive transmission from the spinal cord
arises from the RVM (Millan, 2002). These serotonergic
neurones can exert facilitatory or inhibitory influences onto
dorsal horn neurones depending on the spinal 5-HT receptor
subtype activated and the neuronal cell type within the RVM
(Millan, 2002). Neurones within the RVM are classified into
three types based upon their firing patterns in response to
noxious thermal stimuli. ON-cells increase their firing imme-
diately before a nocifensive response and facilitate nocicep-
tion, while OFF-cells, considered to mediate inhibition, pause
in their firing just prior to a nociceptive withdrawal reflex.
Neutral cells do not appear to play a role in physiological pain
(Heinricher et al., 2009).
Descending facilitation requires the activation of pronoci-
ceptive ON cells (Porreca et al., 2001); however, the pharma-
cology of descending facilitatory pathways remains unclear,
as recordings from RVM neurones suggests that 5-HT contain-
ing neurones are neither ON nor OFF cells (Gao and Mason,
2000). However, converging evidence from recent immuno-
histochemical, behavioural and electrophyisological data
suggests that a proportion of RVM cells activated by noxious
stimuli are serotonergic. Furthermore, a facilitatory effect
mediated by 5-HT, acting at spinal 5-HT3 receptors, wasdemonstrated in models of acute and chronic pain (Oatway
et al., 2004; Rahman et al., 2004; Rahman et al., 2006; Suzuki
et al., 2002; Suzuki et al., 2005; Svensson et al., 2006). These
studies focused on the pronociceptive 5-HT3 receptor, the only
ligand gated cation channel of the 5-HT receptor family, and
its role in mediating descending facilitation.
The electrophysiological consequences of selectively
blocking spinal 5-HT2A receptors on dorsal horn neuronal
activity are similar to the effects we have previously seen with
the selective 5-HT3R antagonist ondansetron (Suzuki et al.,
2002). In the present study, the top dose of ketanserin (100 μg)
significantly inhibited the evoked responses to vF 26 and 60 g
and to 45 and 48 °C heat stimuli, we have previously shown
that ondansetron (100 μg) also reduced the evoked neuronal
responses to these stimuli to a similar degree (Rahman et al.,
2004; Suzuki et al., 2002). Therefore, descending serotonergic
facilitation could equally be mediated through 5-HT acting at
spinal 5-HT2A receptors.4. Conclusion
The present study provides electrophysiological evidence for a
pronociceptive role for spinal 5-HT2 receptors on the evoked
responses of deep dorsal horn wide dynamic range neurones
and supports a pronociceptive role for the 5-HT2A receptor on
spinal nociceptive transmission, without excluding a 5-HT2C
involvement. The data also implicate a role for 5-HT2
receptors in mediating descending facilitation of spinal
nociceptive processing.
Interestingly, evidence from pain patients suggests that
5-HT2A receptor gene polymorphisms could influence indi-
vidual differences in pain sensitivity (Bondy et al., 1999; Pata
et al., 2004) and a recent studyhas demonstrateda link between
single nucleotide polymorphisms in the 5-HT2A receptor gene
and individual analgesic requirements for post-operative pain
management (Aoki et al., 2010). Therefore, unravelling the role
of the 5-HT2Areceptor inpainmodulationpresents a promising
avenue for future drug development and pain therapy.5. Experimental procedures
Male Sprague–Dawley rats (230–250 g) were employed for
this study (Central Biological Services, University College
London, UK). All experimental procedures follow the UK
Animals (Scientific Procedures) Act 1986 and the guidelines
under the International Association for the Study of Pain
(Zimmermann, 1983).
5.1. Electrophysiology
Animals were anaesthetised with isofluorane (1.5–1.7%; 66%
N2O and 33% O2) and a laminectomy was performed to expose
the L4-5 segments of the spinal cord. Extracellular recordings
weremade from ipsilateral deep dorsal horn neurones (lamina
V–VI) usingparylene coated tungstenelectrodes (A-MSystems,
USA). A train of 16 transcutaneous electrical stimuli (2 ms
wide pulses, 0.5 Hz) was applied at 3 times the threshold
current for C-fibres; following which a post-stimulus
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(0–20 ms), Aδ- (20–90 ms) and C-fibres (90–350 ms) were
separated and quantified on the basis of latency. Neuronal
responses occurring after the C-fibre latency band of the
neurone were classed as post-discharge, a result of repeated
stimulation leading to wind-up neuronal hyperexcitability.
The ‘input’ (non-potentiated response), and the ‘wind-up’
(potentiated response, evident by increased neuronal excit-
ability to repeated stimulation) were calculated. Input=
(action potentials evoked by first pulse at 3 times C-fibre
threshold)×total number of pulses (16). Wind-up=(total
action potentials after 16 train stimulus at 3 time C-fibre
threshold)− Input. The peripheral receptive field was also
stimulated using a range of natural stimuli (von Frey
filaments, 2, 8, 26 and 60 g and heat, 42, 45 and 48 °C)
applied over a period of 10 s per stimulus and the evoked
response quantified. The heat stimulus was applied with a
constant water jet onto the centre of the receptive field. Data
were captured and analysed by a CED 1401 interface coupled
to a Pentium computer with Spike 2 software (Cambridge
Electronic Design; PSTH and rate functions).
5.2. Drug administration
Stable control responses to electrical and selected natural
stimuli were established at 20 min intervals prior to drug
administration; this was confirmed with at least 3 consistent
responses (<10%) to all measures. Means of these baseline
responses were calculated and used as the ‘pre-drug’ controls
fromwhich drug effects on subsequent evoked responseswere
tested against. Ketanserin (1, 10 and 100 μg/50 μl saline) was
applied topically to the spinal cord in a cumulative manner or
ritanserin (2 mg/kg)was administered subcutaneously into the
scruff of the neck. DOI (3.6 and 17.8 μg/50 μl saline) was applied
topically to the spinal cord in a cumulative manner; a low
dose of ketanserin (1 μg/50 μl/saline), which does not produce
any effect on neuronal activity on its own, was then
administered to the spinal cord. The two routes were used
because spinal application of a drug will localise its pharma-
cological target to pre-or postsynaptic elements in the dorsal
horn. We used sub cutaneous administration to assess the
effects of systemic exposure. The effect of each drug was
followed over an hour per dose, with tests carried out at 10,
30 and 50 min time points post drug application. The
nature of the drug injection and recording protocol meant
that just one experiment, on one neurone, was performed
per animal used.
5.3. Data analysis
Data are presented as mean±standard error of mean (SEM)
unless otherwise stated. For all studies the maximal effect,
compared with pre-drug baseline control, for each dose was
selected, this varied and was seen at any of the time points
tested i.e. 10, 30 and 50 min post drug administration.
However, in most cases the maximal change in response
was observed at 30 or 50 min post drug application. Drug
effects were then expressed as themeanmaximal effect of the
pre-drug control for each dose. Analyses were performed
using GraphPad Prism version 4 for Apple Macintosh OS 10.4,(GraphPad Software, USA), and for all data, a 95% confidence
interval was used as a measure of statistical significance. All
statistical analyses were performed on raw data using two-
way analysis of variancewith repeatedmeasures (RMANOVA)
for responses to mechanical and thermal stimuli, and if
significant, Bonferroni post hoc tests were performed. The
effect of ketanserin and DOI effect on responses to electrical
stimulation were assessed using a one-way RM ANOVA
followed by Dunnett's post hoc multiple comparisons test
for significant values. The effect of ritanserin on electrical
evoked responseswas assessed using a paired Student's t-test.Acknowledgments
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